Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized,
double-blind, placebo-controlled study designed to assess the safety, tolerability, and
efficacy of IV administered elamipretide (also known as MTP-131, or Bendavia) on a background
of standard-of-care therapy for reduction of reperfusion injury in patients with first time
acute, anterior wall ST-segment elevation myocardial infarction (STEMI).